Trevi Therapeutics Files 8-K on Officer/Director Changes
Ticker: TRVI · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1563880
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Trevi Therapeutics 8-K: Leadership changes and shareholder votes on tap.
AI Summary
Trevi Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting events that occurred on June 11, 2025. The filing indicates changes related to the departure or election of directors and officers, the appointment of certain officers, and compensatory arrangements. It also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if significant, can introduce uncertainty about future strategy and operations.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- June 11, 2025 (date) — Earliest event reported
- June 17, 2025 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers on June 11, 2025?
The filing indicates events related to the departure of directors or certain officers, election of directors, and appointment of certain officers.
Were there any compensatory arrangements for officers mentioned in the filing?
Yes, the filing explicitly lists 'Compensatory Arrangements of Certain Officers' as an item of information.
Did Trevi Therapeutics submit any matters to a vote of its security holders?
Yes, the filing states 'Submission of Matters to a Vote of Security Holders' as an item of information.
What is the principal executive office address for Trevi Therapeutics?
The principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
When is Trevi Therapeutics' fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Trevi Therapeutics, Inc. (TRVI).